IL153546A0 - Acid addition salts of hydropyridine derivatives - Google Patents

Acid addition salts of hydropyridine derivatives

Info

Publication number
IL153546A0
IL153546A0 IL15354601A IL15354601A IL153546A0 IL 153546 A0 IL153546 A0 IL 153546A0 IL 15354601 A IL15354601 A IL 15354601A IL 15354601 A IL15354601 A IL 15354601A IL 153546 A0 IL153546 A0 IL 153546A0
Authority
IL
Israel
Prior art keywords
therapeutic agent
acid addition
addition salts
preventive
addition salt
Prior art date
Application number
IL15354601A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26595526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153546(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL153546A0 publication Critical patent/IL153546A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15354601A 2000-07-06 2001-07-03 Acid addition salts of hydropyridine derivatives IL153546A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000205396 2000-07-06
JP2000266780 2000-09-04
PCT/JP2001/005764 WO2002004461A1 (fr) 2000-07-06 2001-07-03 Sels d'addition acides de dérivés hydropyridine

Publications (1)

Publication Number Publication Date
IL153546A0 true IL153546A0 (en) 2003-07-06

Family

ID=26595526

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15354601A IL153546A0 (en) 2000-07-06 2001-07-03 Acid addition salts of hydropyridine derivatives
IL153546A IL153546A (en) 2000-07-06 2002-12-19 Hydrochloride and full salts of 2 - acetoxy-5 - (α - cyclopropyl - 2 - fluorobenzyl) - 7,6,5,4 - tetrahydro - thiano [2,3 – c] pyridine, their preparation and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153546A IL153546A (en) 2000-07-06 2002-12-19 Hydrochloride and full salts of 2 - acetoxy-5 - (α - cyclopropyl - 2 - fluorobenzyl) - 7,6,5,4 - tetrahydro - thiano [2,3 – c] pyridine, their preparation and pharmaceutical preparations containing them

Country Status (24)

Country Link
US (1) US6693115B2 (cs)
EP (2) EP1298132B1 (cs)
KR (6) KR20030014294A (cs)
CN (1) CN1214031C (cs)
AT (2) ATE346071T1 (cs)
AU (2) AU2001267916B2 (cs)
BR (1) BR0112168A (cs)
CA (2) CA2415558C (cs)
CY (3) CY1107554T1 (cs)
CZ (1) CZ302990B6 (cs)
DE (2) DE60134508D1 (cs)
DK (2) DK1298132T3 (cs)
ES (2) ES2276801T3 (cs)
HK (2) HK1051362A1 (cs)
HU (2) HU230762B1 (cs)
IL (2) IL153546A0 (cs)
MX (1) MXPA03000031A (cs)
NO (1) NO328651B1 (cs)
NZ (1) NZ523416A (cs)
PL (1) PL208386B1 (cs)
PT (2) PT1728794E (cs)
RU (1) RU2238275C1 (cs)
TW (1) TWI290927B (cs)
WO (1) WO2002004461A1 (cs)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311498T3 (es) * 2000-12-25 2009-02-16 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen aspirina.
IL166312A0 (en) * 2002-07-18 2006-01-15 Sankyo Co A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitor
JP2006525328A (ja) * 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー 心疾患の治療方法
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099261A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
CN1318428C (zh) * 2005-02-23 2007-05-30 天津药物研究院 噻吩并吡啶取代的乙酰肼衍生物
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
CA2612315A1 (en) * 2005-06-17 2006-12-28 Eli Lilly And Company Dosage regimen for prasugrel
WO2007024472A2 (en) * 2005-08-19 2007-03-01 Eli Lilly And Company USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES
US8056072B2 (en) 2005-10-31 2011-11-08 Microsoft Corporation Rebootless display driver upgrades
KR101784001B1 (ko) 2006-04-04 2017-10-23 케이지 액퀴지션 엘엘씨 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
US20100204470A1 (en) * 2006-06-27 2010-08-12 Sandoz Ag method for salt preparation
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
US20090291138A1 (en) * 2006-12-07 2009-11-26 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
BRPI0719393B8 (pt) * 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
BRPI0719529B8 (pt) * 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd método para produzir uma preparação sólida
WO2008108291A1 (ja) * 2007-03-02 2008-09-12 Daiichi Sankyo Company, Limited 高純度のプラスグレル塩酸塩の製造方法
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
CZ302135B6 (cs) * 2007-07-09 2010-11-10 Zentiva, A. S. Zpusob výroby 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4, 5, 6, 7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu)
WO2009062044A2 (en) * 2007-11-09 2009-05-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel, and its salts and polymorphs
HU230261B1 (hu) * 2007-11-27 2015-11-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás gyógyszeripari intermedierek előállítására
CN101177430A (zh) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
DE112009000268T5 (de) 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
WO2009129983A1 (en) * 2008-04-21 2009-10-29 Ratiopharm Gmbh Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
ATE482961T1 (de) * 2008-04-25 2010-10-15 Sandoz Ag Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2325187A4 (en) * 2008-08-02 2011-09-28 Lunan Pharm Group Corp PRASUGREL HYDROGENOSULFATE, ITS MEDICINAL COMPOUND AND USE THEREOF
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
CA2757189C (en) 2009-03-31 2016-02-16 Shanghai Institute Of Pharmaceutical Industry Crystals of prasugrel hydrobromate
EP2990051B1 (en) 2009-04-10 2016-10-26 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
EP2429291B1 (en) 2009-05-13 2016-07-06 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EP2451816A4 (en) * 2009-07-06 2013-02-27 Glenmark Generics Ltd CRYSTALLINE FORM OF PRASUGREL HYDROBROMIDE AND PROCESS FOR PREPARING THE SAME
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
CN101993447A (zh) 2009-08-26 2011-03-30 浙江华海药业股份有限公司 一种人工合成普拉格雷的方法
WO2011036533A1 (en) 2009-09-23 2011-03-31 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising prasugrel and triflusal
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
CZ2009763A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a jeho nových farmaceuticky prijatelných solí.
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CZ2009828A3 (cs) 2009-12-09 2011-06-22 Zentiva, K.S. Zpusob prípravy hydrochloridu 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu hydrochloridu) v polymorfní forme B
HU229035B1 (en) * 2009-12-21 2013-07-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing prasurgel
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
EP2360159A1 (de) * 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
EP2545059A1 (en) 2010-03-09 2013-01-16 Synthon BV A process for making prasugrel
KR101184915B1 (ko) 2010-03-11 2012-09-21 한미사이언스 주식회사 고순도 프라수그렐의 제조방법
EP2528924A1 (en) 2010-03-23 2012-12-05 Alembic Pharmaceuticals Limited A process for the preparation of prasugrel hcl salt
EP2377520A1 (de) 2010-03-24 2011-10-19 Ratiopharm GmbH Pharmazeutische Zusammensetzung des Prasugrels
CN102212068A (zh) * 2010-04-06 2011-10-12 刘桂坤 噻吩衍生物及其制备方法和在药物上的应用
CN102212071B (zh) * 2010-04-08 2014-03-26 上海医药工业研究院 普拉格雷盐酸盐乙酸溶剂合物及其结晶和制备方法
US8802854B2 (en) 2010-04-08 2014-08-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of Prasugrel salts
ES2592280T3 (es) 2010-04-19 2016-11-29 Cadila Healthcare Limited Una composición farmacéutica que comprende agentes antiplaquetarios y un agente estimulante de eritropoyesis
WO2012001486A1 (en) * 2010-06-28 2012-01-05 Mayuka Labs Pvt. Ltd. An improved process for the preparation of prasugrel hydrochloride and its intermediates
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
WO2012023145A2 (en) * 2010-08-18 2012-02-23 Hetero Research Foundation Prasugrel hydrochloride crystalline particles
HUP1000565A2 (en) 2010-10-22 2012-05-02 Egis Gyogyszergyar Nyrt Process for the preparation of pharmaceutically active compound and intermediers
CN101985450B (zh) * 2010-11-02 2012-07-11 北京赛科药业有限责任公司 普拉格雷盐及其制备方法
CN102532157A (zh) * 2010-12-16 2012-07-04 瑞阳制药有限公司 普拉格雷的可药用酸加成盐化合物及其制备方法
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
CN102199163A (zh) * 2011-04-01 2011-09-28 中国药科大学 2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN102746318A (zh) * 2011-04-20 2012-10-24 上海信谊药厂有限公司 用于制备普拉格雷盐酸盐的方法
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
CN103702556A (zh) 2011-05-17 2014-04-02 维利科医疗公司 使用唾液酸酶抑制剂改进的血小板保存
CN102838618A (zh) * 2011-06-22 2012-12-26 广东东阳光药业有限公司 一种制备普拉格雷的方法及普拉格雷盐酸盐新晶型
ES2557199T3 (es) 2011-07-28 2016-01-22 Laboratorios Lesvi, S.L. Procedimiento para la preparación de prasugrel
CN103102355A (zh) * 2011-11-09 2013-05-15 丁克 具有旋光性的四氢噻吩并吡啶化合物
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
CA2887083A1 (en) 2012-10-05 2014-04-10 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
WO2014060554A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Prasugrel formulations
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
PL402028A1 (pl) 2012-12-12 2014-06-23 Instytut Farmaceutyczny Sposób wytwarzania postaci polimorficznej B chlorowodorku prasugrelu o czystości farmaceutycznej
HU230649B1 (hu) 2013-01-24 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Javított eljárás prasugrel gyógyszeripari hatóanyag és az 1-ciklopropil-2-(2-fluorofenil)-etanon intermedier előállítására
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
KR102235732B1 (ko) 2013-12-26 2021-04-02 에스케이플래닛 주식회사 쿠폰 관리 시스템 및 방법, 그리고 이를 위한 장치 및 컴퓨터 프로그램이 기록된 기록매체
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
CN104479502A (zh) * 2014-12-31 2015-04-01 江阴市天邦涂料股份有限公司 一种水性防腐涂料
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3106151A1 (en) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
EP3156049A1 (en) 2015-10-15 2017-04-19 Alembic Pharmaceuticals Limited Pharmaceutical composition of prasugrel
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
WO2018073437A1 (en) 2016-10-21 2018-04-26 Laboratorios Lesvi, Sl Pharmaceutical formulations of prasugrel and processes for the preparation thereof
CN106632391A (zh) * 2016-12-23 2017-05-10 山东鲁抗医药股份有限公司 一种盐酸普拉格雷化合物及其制备方法和含有盐酸普拉格雷的药物组合物
US11260071B2 (en) 2017-06-23 2022-03-01 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
KR102063862B1 (ko) 2018-08-09 2020-01-08 한국기술교육대학교 산학협력단 Qr코드 기반의 공유시점관리 시스템
KR102485021B1 (ko) 2020-11-18 2023-01-05 효성중공업 주식회사 델타구조 반도체변압기 기반 에너지 저장장치의 SoC 균등제어 장치 및 방법
KR102491932B1 (ko) 2020-11-18 2023-01-27 현대엠시스템즈 주식회사 통신 방식 가변형 원격 모니터링 제어 시스템 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141894A (en) * 1976-11-02 1979-02-27 Eli Lilly And Company Trans-5a-aryl-decahydrobenzazepines
FR2576901B1 (fr) 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
JP2506376B2 (ja) * 1987-07-16 1996-06-12 三菱化学株式会社 ２−（４−メチルアミノブトキシ）ジフェニルメタン・塩酸塩の製造方法
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
JPH07188168A (ja) * 1993-12-28 1995-07-25 Fujisawa Pharmaceut Co Ltd ジヒドロピリジン化合物およびその製造方法
ES2311498T3 (es) * 2000-12-25 2009-02-16 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen aspirina.
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CZ305314B6 (cs) 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby

Also Published As

Publication number Publication date
HU230762B1 (hu) 2018-03-28
PL208386B1 (pl) 2011-04-29
KR20100105763A (ko) 2010-09-29
CA2703697C (en) 2012-09-04
PT1298132E (pt) 2007-01-31
US6693115B2 (en) 2004-02-17
CA2703697A1 (en) 2002-01-17
CA2415558C (en) 2010-09-14
WO2002004461A1 (fr) 2002-01-17
HUP0301645A3 (en) 2006-05-29
AU6791601A (en) 2002-01-21
CY1110395T1 (el) 2015-04-29
DE60134508D1 (de) 2008-07-31
HU227746B1 (en) 2012-02-28
CN1214031C (zh) 2005-08-10
DE60124712D1 (de) 2007-01-04
HK1051362A1 (en) 2003-08-01
DE60124712T2 (de) 2007-09-13
RU2238275C1 (ru) 2004-10-20
IL153546A (en) 2007-03-08
CY2009011I1 (el) 2010-07-28
CY1107554T1 (el) 2010-07-28
TWI290927B (en) 2007-12-11
PT1728794E (pt) 2008-07-15
NO20030022D0 (no) 2003-01-03
EP1298132A4 (en) 2004-03-10
KR20030014294A (ko) 2003-02-15
MXPA03000031A (es) 2003-10-15
KR20120062906A (ko) 2012-06-14
AU2001267916B2 (en) 2004-09-09
HUP0301645A2 (hu) 2003-09-29
EP1728794B1 (en) 2008-06-18
ES2276801T3 (es) 2007-07-01
ATE346071T1 (de) 2006-12-15
BR0112168A (pt) 2003-09-02
US20030134872A1 (en) 2003-07-17
DK1728794T3 (da) 2008-09-22
HUP1100350A2 (en) 2003-09-29
KR20090033917A (ko) 2009-04-06
KR20080021152A (ko) 2008-03-06
ES2308633T3 (es) 2008-12-01
CN1452624A (zh) 2003-10-29
CY2009011I2 (el) 2010-07-28
ATE398624T1 (de) 2008-07-15
HK1096684A1 (en) 2007-07-20
CZ302990B6 (cs) 2012-02-08
DK1298132T3 (da) 2007-03-12
CA2415558A1 (en) 2002-01-17
EP1728794A1 (en) 2006-12-06
NO328651B1 (no) 2010-04-19
NZ523416A (en) 2004-10-29
PL359393A1 (en) 2004-08-23
EP1298132A1 (en) 2003-04-02
KR20130118395A (ko) 2013-10-29
NO20030022L (no) 2003-03-05
CZ200318A3 (cs) 2003-05-14
EP1298132B1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
IL153546A0 (en) Acid addition salts of hydropyridine derivatives
IL156456A0 (en) Pharmaceutical compositions containing aspirin
RU2003100082A (ru) Кислотные аддитивные соли производных гидропиридина
DE69219807D1 (de) Thienopyridinderivate und diese enthaltende pharmazeutische Zubereitungen
IE883360L (en) Indan derivatives and process for preparation thereof
AU631023B2 (en) Tetrahydronaphthalene derivatives and preparation thereof
Plotkine et al. Oral administration of isosorbide dinitrate inhibits arterial thrombosis in rats
EP1236735A4 (en) BENZAMIDINE DERIVATIVES
GR3008250T3 (cs)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed